PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals — Investor Day (March 2021)

77 slides from PhaseBio Pharmaceuticals's investor day presentation, Mar 15, 2021

  1. Slide 1: Bentracimab Program Update

    Bentracimab Program Update MARCH 15, 2021

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business str

  3. Slide 3: Introduction and corporate update

    Introduction and corporate update Jonathan Mow Chief Executive Officer, PhaseBio

  4. Slide 4: A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company

    Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone Target2 Bentracimab Reversal of Ticagrelor Antiplatelet Activity Q2 2021 Publication of Phase 2A trial results Pemziviptadil Pulmonary Arterial Hypertension (PAH) 2H 2021 Report Phase 2B data PB6440 Resistant Hypertens

  5. Slide 5: Pemziviptadil: Harnessing VIP to Create a Stable, Long-Acting Drug

    PRECLINICAL STUDIES Support Clinical Development for: • Pulmonary Arterial Hypertension • DMD Cardiomyopathy • Heart Failure (Chemotherapy-Induced HF or HFpEF) • Cystic Fibrosis MECHANISM OF ACTION VIA VPAC2 RECEPTOR • Potent vasodilator and immunomodulator • Anti-inflammatory and anti-fibrotic • Ca

  6. Slide 6: High Unmet Need in an Orphan Disease

    High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) • High unmet need for novel disease-modifying PAH therapies for greater efficacy All 3 approved drug classes in PAH are vasodilators: prostacyclin, endothelin, and nitric oxide pathways Patients inevit

  7. Slide 7: Pemziviptadil Clinical Development Activities to Date

    Pemziviptadil Clinical Development Activities to Date Have Supported Advancement into Phase 2 Efficacy Studies 7 PHASE 1 Studies Completed PHASE 2 PAH Studies • Well tolerated for a week over broad range of exposure; no drug-related SAEs reported • Prolonged PK/PD profile over 1 week • VIP activity

  8. Slide 8: Why We Are Here Today

    Why We Are Here Today 8 What is Bentracimab • Highlight features of the P2Y12 class • Describe unmet need for reversal • Outline potential future directions Current Situation • Review clinical data and progress • Global regulatory path forward • Manufacturing at commercial scale Future Potential • G

  9. Slide 9: Key Take-Aways

    Key Take-Aways 9 • Bentracimab clinical development program is enrolling ahead of schedule Global regulatory path for bentracimab is clear and supported by the REVERSE-IT trial • Need for P2Y12-inhibitor reversal is completely unmet in today’s medical practice Ticagrelor has a best-in-class efficacy

  10. Slide 10: Agenda and presenters

    Time (EST) Section Presenter 12:00 pm Introduction and general corporate update Jonathan Mow Chief Executive Officer 12:10 pm Overview of bentracimab and ticagrelor Deepak L. Bhatt, MD, MPH Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital Heart & Vascular Ce

  11. Slide 11: Overview of Bentracimab and Ticagrelor

    Overview of Bentracimab and Ticagrelor Deepak L. Bhatt, MD, MPH Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School

  12. Slide 12: Urgent surgery or intervention and ticagrelor reversal

    12 URGENT SURGERY OR INTERVENTION • Currently oral P2Y12 agents, including ticagrelor, require a 5-day washout prior to surgery1,2 Urgent surgery often cannot wait 5 days Higher thrombotic risk during washout • In Phase 1 and Phase 2A studies, bentracimab observed to immediately and sustainably reve

  13. Slide 13: P2Y12 Inhibitors Are Linked to Uncontrolled Bleeding and Complicate Surgeries

    P2Y12 Inhibitors Are Linked to Uncontrolled Bleeding and Can Complicate Surgeries and Invasive Procedures 13 Uncontrolled Major Bleeding Urgent Surgeries and Invasive Procedures • Intracranial • Subdural • Subarachnoid • Gastrointestinal • Retroperitoneal • Traumatic injuries • Post-operative bleedi

  14. Slide 14: Intracranial Hemorrhage Case Study

    Intracranial Hemorrhage Case Study1 Highlights the Delicate Balance Between Managing the Bleed and Protecting the Stent • A 59-year old male with a history of coronary artery disease, hypertension and hyperlipidemia reported sudden onset headache, mild dysmetria and severe nausea. Medical history in

  15. Slide 15: Oral P2Y12 Inhibitor Class: Only Ticagrelor Can Be Reversed

    Oral P2Y12 Inhibitor Class: Only Ticagrelor Can Be Reversed 15 Clopidogrel Prasugrel Ticagrelor Receptor blockade Irreversible Irreversible Reversible Prodrug Yes Yes No Half-life of parent drug ≈6 h <5 min 6–12 h Half-life of active metabolite 30 mins Distribution half-life, 30–60 mins 8–12 h Elimi

  16. Slide 16: Bentracimab: Well-Characterized Mechanism of Ticagrelor Reversal

    Bentracimab: Well-Characterized Mechanism of Ticagrelor Reversal 16 1. 2. 3. 4. 5. 6. ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation Bentracimab binds to free ticagrelor with very high affinity This is a reversible proc

  17. Slide 17: Ticagrelor Clinical Evidence Supports Broad Use

    Ticagrelor Clinical Evidence Supports Broad Use • Ticagrelor clinical development program encompassed six major outcomes trials enrolling nearly 100,000 patients PLATO, PEGASUS-TIMI-54, SOCRATES, EUCLID, THALES, and THEMIS The four trials linked to the current ticagrelor prescribing label are highli

  18. Slide 18: THEMIS Trial and Recent Ticagrelor Label Expansion

    THEMIS Trial and Recent Ticagrelor Label Expansion 18 • Patients with stable coronary artery disease (CAD) and diabetes mellitus (T2D) are at high risk for cardiovascular events • Data from the THEMIS1 trial highlights the potential for ticagrelor to reduce the risk of ischemic cardiovascular events

  19. Slide 19: THEMIS PCI: Subgroup Analysis Highlights Ticagrelor Net Clinical Benefit

    THEMIS PCI: Subgroup Analysis Highlights Ticagrelor Net Clinical Benefit • Prespecified subgroup of patients • Fulfill major THEMIS inclusion criterion of having a history of previous percutaneous coronary intervention (PCI) • Data suggest significantly favorable effect on primary efficacy endpoint,

  20. Slide 20: Stent Thrombosis: DAPT Complicates Surgery for Post-PCI Patients

    • Following coronary stenting a significant number of patients undergo noncardiac surgery May require DAPT interruption • Poses a significant clinical dilemma: DAPT interruption exposes patients to potential risk of stent thrombosis, perioperative myocardial infarction, or both Continuing DAPT may b

  21. Slide 21: Current Paradigm for Bridging Oral P2Y12 Patients Ahead of Surgery

    Current Paradigm for Bridging Oral P2Y12 Patients Ahead of Surgery 1 211. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation. 2017;136(20):1955–1975. doi: 10.1161/CIRCULATI

  22. Slide 22: Hypothetical Future Paradigm Following Potential Bentracimab Launch

    Hypothetical Future Paradigm for Bridging Oral P2Y12 Patients Ahead of Surgery Following Potential Bentracimab Launch 22 • Bentracimab could potentially change the way surgeries and invasive procedures are managed in P2Y12 patients - Switching from clopidogrel or prasugrel to ticagrelor is well defi

  23. Slide 23: First Randomized Human Experience with a Ticagrelor Reversal Agent

    23 First Randomized Human Experience with a Ticagrelor Reversal Agent Deepak L. Bhatt, MD, MPH, Charles V. Pollack, MD, Jeffrey I. Weitz, MD, Lisa K. Jennings, PhD, Sherry Xu, PhD, Susan E. Arnold, PhD, Bret R. Umstead, MS, Michael C. Mays, BS, John S. Lee MD, PhD

  24. Slide 24: Onset and Duration of Ticagrelor Reversal – VerifyNow P2Y12 (PRU)

    24 Onset and Duration of Ticagrelor Reversal – VerifyNow P2Y12 (PRU) Platelet aggregation as observed in the PB2452 and placebo groups (Cohorts 7-10) PRU= Platelet Reactivity Units Due to the small sample size for cohort 9 (n=3), statistical testing was not performed. For Cohorts 9 and 10, no 10-hou

  25. Slide 25: Onset and Duration of Ticagrelor Reversal – VerifyNow P2Y12 (PRU)

    25 Onset and Duration of Ticagrelor Reversal – VerifyNow P2Y12 (PRU) Platelet aggregation as observed in the PB2452 and placebo groups (Cohorts 7-10) PRU= Platelet Reactivity Units Due to the small sample size for cohort 9 (n=3), statistical testing was not performed. For Cohorts 9 and 10, no 10-hou

  26. Slide 26: Onset and Duration of Ticagrelor Reversal – VerifyNow P2Y12 (PRU)

    26 Onset and Duration of Ticagrelor Reversal – VerifyNow P2Y12 (PRU) Platelet aggregation as observed in the PB2452 and placebo groups (Cohorts 7-10) PRU= Platelet Reactivity Units Due to the small sample size for cohort 9 (n=3), statistical testing was not performed. For Cohorts 9 and 10, no 10-hou

  27. Slide 27: Platelet Aggregation with Low- and High-Dose ADP

    27 Platelet Aggregation with Low- and High-Dose ADP Mean platelet aggregation by LTA using 5 µM ADP (top) or 20 µM ADP (bottom) as agonist LTA: light transmission aggregometry; ADP: adenosine diphosphate Platelet hyper-reactivity, or rebound, between 5 minutes and 48 hours was ruled out by the respo

  28. Slide 28: Treatment-emergent Adverse Events

    28 Treatment-emergent Adverse Events Preferred Term All Placebo (N=16) n (%) All PB2452 (N=48) n (%) Total Number of TEAEs 3 27 Number of volunteers with at Least 1 TEAE 2 (12.5) 17 (35.4) Infusion site bruising 0 4 (8.3) Medical device site reaction 0 3 (6.3) Infusion site extravasation 0 2 (4.2) V

  29. Slide 29: Conclusion

    29 Conclusion • Using multiple assays in healthy volunteers, PB2452, a specific reversal agent for ticagrelor, provided immediate and sustained reversal of ticagrelor’s antiplatelet effects. Bhatt DL, Pollack CV, Weitz JI, et al. N Engl J Med. 2019.

  30. Slide 30: Conclusion

    30 Conclusion • Using multiple assays in healthy volunteers, PB2452, a specific reversal agent for ticagrelor, provided immediate and sustained reversal of ticagrelor’s antiplatelet effects. • The ability to reverse ticagrelor’s antiplatelet effects rapidly could distinguish it from other antiplatel

  31. Slide 31: Conclusion

    31 Conclusion • Using multiple assays in healthy volunteers, PB2452, a specific reversal agent for ticagrelor, provided immediate and sustained reversal of ticagrelor’s antiplatelet effects. • The ability to reverse ticagrelor’s antiplatelet effects rapidly could distinguish it from other antiplatel

  32. Slide 32: Clinical Update: Phase 1 and 2A Studies

    Clinical Update John Lee, MD, PhD Chief Medical Officer, PhaseBio Phase 1 and 2A Studies

  33. Slide 33: Bentracimab Profile from Phase 1 Study

    Bentracimab Profile from Phase 1 Study 33 Article available at https://www.nejm.org Slides available for download at https://www.ACC.org • A specific reversal agent for ticagrelor, provided immediate and sustained reversal of ticagrelor’s antiplatelet effects • Breakthrough Therapy designation from

  34. Slide 34: Bentracimab Phase 2A Study Objectives and Design

    Bentracimab Phase 2A Study Objectives and Design 34 Objectives • Dose translation from Phase 1 to older and elderly population • Establish VerifyNow as primary biomarker for pivotal studies • Provide regimen for Phase 3 CYP3A patients (FDA request) Study design: Randomized, double-blind, PBO control

  35. Slide 35: Bentracimab Phase 2A Study Results

    Bentracimab Phase 2A Study Results 35 In 50-80 year olds, nearly identical reversal profile as observed in Phase 1 study • Immediate reversal within 5 minutes of initiation of PB2452, sustained 20-24 hour reversal • No evidence of prothrombotic rebound effect post-reversal • Per FDA request, we iden

  36. Slide 36: Bentracimab Pivotal Program

    bentracimab Pivotal Program John Lee, MD, PhD Chief Medical Officer, PhaseBio Phase 2B and Phase 3 REVERSE-IT

  37. Slide 37: Pivotal Trials: Prior Publicly Guided Timelines

    bentracimab Bentracimab (PB2452) Pivotal Trials: Prior Publicly Guided Timelines 37 Phase 2B trial: randomized, double-blind, placebo-controlled trial in volunteers 50-80 years old (N=200) • Enrollment ongoing in US and Canada, 3:1 randomization (active:placebo) • Primary endpoint is reversal measur

  38. Slide 38: REVERSE-IT Phase 3 Study and Primary Endpoints

    bentracimab REVERSE-IT Phase 3 Study and Primary Endpoints 38 REVERSE-IT trial in ticagrelor patients with major bleeding or who need urgent surgery (N=100 for Interim Analysis, N=200 total) Screening (pre-dose) Informed consent Day 1 • VerifyNow • PB2452/tica PK • Central lab (hgb) • Hemostasis Inc

  39. Slide 39: REVERSE-IT Trial Global Footprint

    bentracimab REVERSE-IT Trial Global Footprint 39 REVERSE-IT trial in ticagrelor patients with major bleeding or who need urgent surgery (N=100 for Interim Analysis, N=200 total) Screening (pre-dose) Central Adjudication • Inclusion criteria • Hemostasis • Thrombotic Events REVERSE-IT sites are enrol

  40. Slide 40: REVERSE-IT Enrollment Ahead of Original Projection

    bentracimab REVERSE-IT Enrollment Ahead of Original Projection 40 REVERSE-IT has enrolled 60 of the first 100 patients for the Interim Analysis • Enrollment is robust and ahead of initial projections despite COVID pandemic • Subjects include both major bleeding and urgent surgery/procedure patients

  41. Slide 41: REVERSE-IT Clinical Data Objectives

    bentracimab REVERSE-IT Clinical Data Objectives 41 REVERSE-IT Data Safety Monitoring Board (DSMB) concluded first meeting in January 2021 • No concerning safety signals identified in first 25 enrolled patients • Unanimous recommendation to continue REVERSE-IT as currently designed REVERSE-IT efficac

  42. Slide 42: REVERSE-IT Predominance of Surgical Patients

    bentracimab REVERSE-IT Predominance of Surgical Patients 42 Pandemic impact on bleeding patient admissions • Reduction in hospital admissions for major adverse spontaneous events like bleeding • Broad, global moratorium on clinical research and furloughs of research staff • Smaller REVERSE-IT footpr

  43. Slide 43: REVERSE-IT Plan to Accelerate Bleeding Patient Recruitment

    bentracimab REVERSE-IT Plan to Accelerate Bleeding Patient Recruitment 43 Internal resources re-allocated to bleeding site activation to widen catchment area • Prioritizing sites to lean towards bleeding recruitment – neurosurgery, stroke centers, trauma • Supplement surgical footprint with expanded

  44. Slide 44: Revised Timelines of Bentracimab Program

    bentracimab Revised Timelines of Bentracimab Program 44 Targeted timelines could be impacted by the continued scope and duration of the COVID-19 pandemic NEJM= New England Journal of Medicine, EOP1=End-of-Phase 1 Meeting, BLA=Biologics License Application 2019 2020 2021 2022 2023 Phase 2B: 50-80 yea

  45. Slide 45: Revised Timelines of Bentracimab Program

    bentracimab Revised Timelines of Bentracimab Program 45 2019 2020 2021 2022 2023 Phase 2B: 50-80 year old volunteersPhase 2APhase 1 NEJM FDA Breakthrough Therapy FDA EOP1 EMA PRIME Designation N=200, 150 randomized to receive PB2452 N=100, major bleeding + urgent surgery patients Final N=200 Post-ap

  46. Slide 46: Regulatory

    Regulatory Lauren Richardson Global Head of Regulatory Affairs and Quality Assurance, PhaseBio

  47. Slide 47: Bentracimab Regulatory Interactions and Designations

    EMA: • Scientific Advice Face-to-face interaction and written guidance in general agreement with proposed development plan for bentracimab • PRIME designation1 Granted to support medicines that demonstrate the potential to address substantial unmet medical need Potentially expedites the review and a

  48. Slide 48: Bentracimab: Regulatory Highlights

    Bentracimab: Regulatory Highlights • Numerous regulatory interactions and planned future interactions Acceptance of clinical development program and study design Agreement with toxicity and CMC strategy Clarification of expectations for approval packages (multi-disciplinary) • Future interactions* C

  49. Slide 49: Revised Clinical Timeline Provides Opportunity for Accelerated Approval

    Revised Clinical Timeline Provides Opportunity for Accelerated Approval 49 Accelerated and Conditional Approval Packages • Initial BLA/MAA filing package based on a minimum safety requirement of at least 100 Phase 3 patients • Current Phase 3 protocol - No requirement for minimum number of bleeding

  50. Slide 50: Global Regulatory Planning and Approval Strategy

    Global Regulatory Planning and Approval Strategy Global Phase 3 protocol with regional acceleration programs for serious and unmet need 50 Initial marketing applications aligned with clinical studies, highest ticagrelor use areas and regions with acceleration programs. Initial filing planned with in

  51. Slide 51: Manufacturing & Product Presentation

    Manufacturing & Product Presentation Susan Arnold, PhD Vice President of Preclinical & CMC, PhaseBio

  52. Slide 52: Manufacturing: Drug Substance/API

    Drug Substance/API • Bentracimab drug substance is manufactured in E. coli Simple straight-forward four column purification process (no specialized resins) • Successful scale up of the FIH manufacturing process to a 17,000L bioreactor scale at BioVectra (Canada) No change in strain No major changes

  53. Slide 53: BioVectra – Commercial Supply Agreement

    • On March 10, 2021, PhaseBio entered into a 10-year Commercial Supply Agreement for Drug Substance/API manufacturing of bentracimab • 5 manufacturing facilities located in eastern Canada Supporting multiple commercial products Customers include top pharma and biotech companies • Facility located in

  54. Slide 54: Manufacturing Drug Product

    Manufacturing Drug Product • Drug product manufacturing consists of thawing, pooling, filtration/fill • No further formulation or extensive manipulation required • Validation of the commercial process is planned for late 2021 We plan to file a complete CMC manufacturing package at BLA filing 54

  55. Slide 55: Phase 3 and Commercial Launch Presentation

    Launch Presentation • 100 mg/mL bentracimab Liquid stable Filled at 6 g/vial (3 vials per dose) • Ready to use refrigerated formulation No dilution or manipulation of the drug product required Does not require preparation in a hospital pharmacy • 2-year shelf-life Real time stability currently suppo

  56. Slide 56: Hospital Pharmacy Perspective

    Hospital Pharmacy Perspective John Fanikos, BS Pharm, MBA Executive Director of Pharmacy Services at Brigham and Women's Hospital

  57. Slide 57: Antiplatelet Therapy, the Landscape, the Need for Bentracimab: the Pharmacist's View

    57 Antiplatelet Therapy, the Landscape, the Need for Bentracimab: the Pharmacist’s View John Fanikos, BS Pharm, MBA Brigham and Women’s Hospital Monday, March 15, 2021

  58. Slide 58: Outline

    58 Outline •Antiplatelet agents and patterns of use •Guidelines and Expert Opinion •Case examples-The need for a reversal agent • Bleeding • Unplanned surgeries •Current Hospital Support Structure • Summary

  59. Slide 59: Antiplatelet Therapy: An Ongoing Concern

    59 Prasugrel Ticagrelor Clopidogrel Fatani N, et al. J Thromb and Thrombolysis, 2019;48:539-41. 131,431 123,825 121,093 118,752 107,253 101,466 0 5 10 15 20 25 30 0 20,000 40,000 60,000 80,000 100,000 120,000 140,000 C u m u la ti v e P e rc e n t O cc u rr e n ce s (0 0 0 ) CDC. See https://www.cdc

  60. Slide 60: Antiplatelet Therapy: An Ongoing Concern

    60BWH Internal data FY19-20 Zekery-Saad SA, et al. J Thromb Thrombolysis 2021; 51 (2):405-419. BWH Monthly P2Y12 Use Antiplatelet Therapy: An Ongoing Concern 0 500 1,000 1,500 2,000 2,500 Clopidogrel Prasugrel Ticagrelor Covid Pandemic Peak Monthly Average AC, 70% SAPT+AC, 29% DAPT+AC, 1% Single and

  61. Slide 61: Antiplatelet Therapy: Pharmacodynamics

    61 Swan D, et al. Blood Reviews 2020; https://doi.org/10.1016/j.blre.2019.100619. Antiplatelet Therapy: Pharmacodynamics Agent Mechanism Route Action Half-Life Time to Recovery Aspirin COX-1 inhibitor Oral Irreversible 15-20 minutes 5-7 days Clopidogrel P2Y12 Inhibitor 6-8 hours 7 days Prasugrel 7 h

  62. Slide 62: Surgery and Bleeding Recommendations

    62 Surgery Recommendations Recommendations for Bleeding Tafur A, et al. Interrupt 2-3 days, Cangrelor bridge, Platelet transfusion. None.Patel IJ, et al Hold 5 days before surgery, Consult Cardiology. Filipescu DC, et al. Interrupt for minimum amount of time, Cangrelor bridge. Desmopressin, Factor V

  63. Slide 63: Case Presentation: Male with Headache

    63 Case Presentation: 63 year old male with Headache Chief Complaint: • New onset headache, N+V, dizziness, new arm paralysis. Past Medical History: • COPD, lung cancer in remission (s/p resection in 2012), HFrEF (EF 30%), DM, CAD, PAD-s/p bypass graft. • Taking ASA + Clopidogrel. ED Course: • CT He

  64. Slide 64: Case Presentation: Female with History of Breast Cancer

    64 Case Presentation: 70 year old female with History of Breast Cancer Chief Complaint: • Chest wall pain, worsens with movement and inspiration. Past Medical History: • Recent MI treated with drug eluting stent (ASA + Ticagrelor). Imaging: • Chest CT showed an anterior RUL mass measuring approximat

  65. Slide 65: Case Presentation: Female with Atherosclerosis

    65 Case Presentation: 54 year old female with Atherosclerosis Chief Complaint: • Woke up from sleep with a tearing pain in her neck radiating to shoulders. • Progressive paralysis of lower extremities. Past Medical History: • Diffuse CAD, MI-stent LAD 2008, MI-stent 2020, hip arthroplasty, osteoarth

  66. Slide 66: Stewardship Structure

    66 Stewardship Structure Pharmacy Hematology Cardiology Hemostatic and Antithrombotic Stewardship Hospital Administration Pharmacy and Therapeutics Committee • Antithrombotic Reversal and Bleeding Management • Andexanet, Idarucizumab • Clotting Factor Management • Ensure appropriate use of agents (i

  67. Slide 67: Antithrombotic Stewardship: Value-Added Service

    67 Antithrombotic Stewardship: Value-Added Service Lewin AR, et al. Crit Pathways in Cardiol 2020, 19(4):178-86. Filapescu DC, et al. Curr Opin Anesthesiol 2020;33;454-62.

  68. Slide 68: Trauma, ICH patients on anticoagulation

    68 Trauma, ICH patients on anticoagulation (AC) Continuous Quality Improvement Minutes • Hold anticoagulant & give a Reversal Agent • Send laboratory analysis for baseline values and if necessary to modify therapy • Initiate prior to lab being drawn or resulted Bleeding with Hemodynamic Changes Hour

  69. Slide 69: Summary

    69 Summary • Antiplatelet therapy is common. • Antiplatelet therapy in combination (ASA, Anticoagulants) • Recommendations for how to stop antiplatelet activity vary. • There is no “ideal” approach. • Complications with patient are common. • A tool (bentracimab) to halt antiplatelet activity is need

  70. Slide 70: Commercial Opportunity

    Commercial Opportunity Michael York Vice President of Corporate Development & Commercial Strategy, PhaseBio

  71. Slide 71: ~42M Global Patients Estimated on P2Y12 Inhibitors

    ~42M Global Patients Estimated on P2Y12 Inhibitors: The Foundation of ACS Therapy 71 2019 P2Y12 Class: Top 20 Countries by Patient Count ~3.3M Ticagrelor Patients By Key Markets Iqvia®, PhaseBio Analysis of MIDAS Data – Full Year 2019 Country Clopidogrel Prasugrel Ticagrelor Country Total CHINA 7,35

  72. Slide 72: Bentracimab May Fundamentally Change Prescribing in the P2Y12 Class

    Introduction of Bentracimab May Fundamentally Change Prescribing in the P2Y12 Class 72 Ticagrelor Differentiation vs. clopidogrel Now Post Bentracimab Launch Post LOE of ticagrelor Efficacy ✓ ✓ ✓ Safety ≈ (no reversal agent) ✓ ✓ Price ✕ (branded vs. generic) ✕ (branded vs. generic) ✓

  73. Slide 73: PhaseBio Strategy to Drive Hospital Focused Launch

    PhaseBio Strategy to Drive Hospital Focused Launch 73 Pre-Launch Imperatives Establish Burden of Bleeds Identify and Remove Barriers to Adoption Segment and Target Hospitals and IDNs Establish Launch Capabilities Build Brand Awareness Stocked • Inclusion in order sets at targeted institutions • Enab

  74. Slide 74: Lipitor Analog Points to Potential Increase in Post-LOE Ticagrelor Share

    Lipitor Analog Points to Potential ~2.5X Increase in Post-LOE Ticagrelor Market Share Within the P2Y12 Inhibitor Class 74 51.1% 0% 10% 20% 30% 40% 50% 60% M o le c u le S ta n d a rd U n it s S h a re Atorvastatin/Lipitor Fluvastatin/Lescol Lovastatin/Altoprev Pitavastatin/Livalo Pravastatin/Pravach

  75. Slide 75: Bentracimab – Well Positioned to Support Hospital Based Clinicians

    Bentracimab – Well Positioned to Support Hospital Based Clinicians 75 Immediate 5 Minutes Return to Normal Platelet Function Sustained 20+ Hours Reversal of ticagrelor antiplatelet effects Specific 100x* Preferential binding affinity to ticagrelor Unmet 0 Current therapeutic interventions *Bentracim

  76. Slide 76: Closing Remarks

    Closing Remarks Jonathan Mow Chief Executive Officer, PhaseBio

  77. Slide 77: Key Take-Aways

    Key Take-Aways 77 • Bentracimab clinical development program is enrolling ahead of schedule Global regulatory path for bentracimab is clear and supported by the REVERSE-IT trial • Need for P2Y12-inhibitor reversal is completely unmet in today’s medical practice Ticagrelor has a best-in-class efficac

PhaseBio Pharmaceuticals — Investor Day (March 2021) on 6ix